

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	516	536/21	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:12
L2	158	I1 and glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:49
L3	61	I2 and depolymeriz\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:49
L4	0	I3 and (electron NEAR beam)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:49
L5	907	536/53	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:49
L6	65	I5 and glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:50
L7	8	I6 and depolymeriz\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:50
L8	0	I7 and (electron NEAR beam)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:51
L9	1862	536/124	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:50
L10	66	I9 and glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:51
L11	19	I10 and depolymeriz\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:51

## EAST Search History

L12	0	l11 and (electron NEAR beam)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:51
L13	290	204/157.6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:51
L14	66	l10 and glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L15	19	l14 and depolymeriz\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L16	0	l15 and (electron NEAR beam)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:53
L17	106	204/157.63	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L18	1	l17 and glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L19	5626	glycosaminoglycan	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L20	257	l19 and depolymeriz\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:52
L21	4	l20 and (electron NEAR beam)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/08/10 09:53

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:58:30 ON 10 AUG 2006

=> file polymer medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'APOLLIT' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (c) 2006 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 09:58:54 ON 10 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (c) 2006 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 09:58:54 ON 10 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 09:58:54 ON 10 AUG 2006

Compendex Compilation and Indexing (C) 2006

Elsevier Engineering Information Inc (EEI). All rights reserved.

Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'NTIS' ENTERED AT 09:58:54 ON 10 AUG 2006

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2006)

FILE 'PASCAL' ENTERED AT 09:58:54 ON 10 AUG 2006

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 09:58:54 ON 10 AUG 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 09:58:54 ON 10 AUG 2006

COPYRIGHT (C) 2006 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 09:58:54 ON 10 AUG 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:58:54 ON 10 AUG 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 09:58:54 ON 10 AUG 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 09:58:54 ON 10 AUG 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 09:58:54 ON 10 AUG 2006  
COPYRIGHT (C) 2006 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 09:58:54 ON 10 AUG 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:58:54 ON 10 AUG 2006

FILE 'BIOSIS' ENTERED AT 09:58:54 ON 10 AUG 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 09:58:54 ON 10 AUG 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s glycosaminoglycan  
L1 116925 GLYCOSAMINOGLYCAN

=> s l1 and heparin  
L2 32089 L1 AND HEPARIN

=> s l2 and depolym?  
L3 947 L2 AND DEPOLYM?

=> s l3 and (electron(a)beam)  
16 FILES SEARCHED...  
L4 11 L3 AND (ELECTRON(A) BEAM)

=> dis l4 1-11 bib abs

L4 ANSWER 1 OF 11 USPATFULL on STN  
AN 2006:27521 USPATFULL  
TI Biodegradable ocular devices, methods and systems  
IN Varner, Signe E., Los Angeles, CA, UNITED STATES  
Guire, Patrick E., Eden Prairie, MN, UNITED STATES  
Taton, Kristin S., Little Canada, MN, UNITED STATES  
Wen, Jie, Eden Prairie, MN, UNITED STATES  
Beeley, Nathan R.F., Irvine, CA, UNITED STATES  
Lawin, Laurie R., New Brighton, MN, UNITED STATES  
Hergenrother, Robert W., Eden Prairie, MN, UNITED STATES  
Chappa, Ralph A., Prior Lake, MN, UNITED STATES  
Anderson, Aron B., Minnetonka, MN, UNITED STATES  
PI US 2006024350 A1 20060202  
AI US 2005-165884 A1 20050624 (11)  
PRAI US 2004-583171P 20040624 (60)  
US 2005-669701P 20050408 (60)  
DT Utility  
FS APPLICATION  
LREP KARRIE WEAVER, Kagan Binder, PLLC, Suite 200, 221 Main Street North,  
Stillwater, MN, 55082, US  
CLMN Number of Claims: 49  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 5734  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides implantable medical devices that are fabricated

of biodegradable materials for delivery of bioactive agent to limited access regions of a patient's body, such as the eye. The invention further provides methods of treatment utilizing the devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 11 USPATFULL on STN  
AN 2006:21116 USPATFULL  
TI Biodegradable implantable medical devices, methods and systems  
IN Guire, Patrick E., Eden Prairie, MN, UNITED STATES  
Taton, Kristin S., Little Canada, MN, UNITED STATES  
Wen, Jie, Eden Prairie, MN, UNITED STATES  
DeWitt, David M., Minneapolis, MONGOLIA  
Hergenrother, Robert W., Eden Prairie, MN, UNITED STATES  
Anderson, Aron B., Minnetonka, MN, UNITED STATES  
PI US 2006018948 A1 20060126  
AI US 2005-165993 A1 20050624 (11)  
PRAI US 2004-583171P 20040624 (60)  
DT Utility  
FS APPLICATION  
LREP KARRIE WEAVER, Kagan Binder, PLLC, Suite 200, 221 Main Street North, Stillwater, MN, 55082, US  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4502

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides implantable intraluminal medical devices that are fabricated of biodegradable materials. The invention further provides methods of treatment utilizing the devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 11 USPATFULL on STN  
AN 2005:138016 USPATFULL  
TI Methods for conducting assays for enzyme activity on protein microarrays  
IN Zhou, Fang X., New Haven, CT, UNITED STATES  
Schweitzer, Barry, Cheshire, CT, UNITED STATES  
PI US 2005118665 A1 20050602  
AI US 2004-865431 A1 20040609 (10)  
RLI Continuation-in-part of Ser. No. US 2003-458720, filed on 9 Jun 2003, PENDING  
DT Utility  
FS APPLICATION  
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 6014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of conducting assays for enzymatic activity on microarrays useful for the large-scale study of protein function, screening assays, and high-throughput analysis of enzymatic reactions. The invention relates to methods of using protein chips to assay the presence, amount, activity and/or function of enzymes present in a protein sample on a protein chip. In particular, the methods of the invention relate to conducting enzymatic assays using a microarray wherein a protein and a substance are immobilized on the surface of a solid support and wherein the protein and the substance are in proximity to each other sufficient for the occurrence of an enzymatic reaction between the substance and the protein. The invention also relates to microarrays that have an enzyme and a substrate immobilized on their surface wherein the enzyme and the substrate are in proximity to each other sufficient for the occurrence of an enzymatic reaction

between the enzyme and the substrate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 11 USPATFULL on STN  
AN 2005:125479 USPATFULL  
TI Medical device with multiple coating layers  
IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard J., Rochester, NY, UNITED STATES  
PI US 2005107870 A1 20050519  
AI US 2004-923579 A1 20040820 (10)  
RLI Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul  
2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on  
14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916,  
filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part  
of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb  
2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on  
29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543,  
filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US  
2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser.  
No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609  
DT Utility  
FS APPLICATION  
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408, US  
CLMN Number of Claims: 62  
ECL Exemplary Claim: 1  
DRWN 54 Drawing Page(s)  
LN.CNT 18628  
AB An implantable medical device that contains two coating layers disposed  
above at least one of its surfaces. The first coating layer contains a  
biologically active material; and the second coating layer contains a  
polymeric material and nanomagnetic material disposed on the first  
coating layer; the second coating layer is substantially free of the  
biologically active material. The nanomagnetic material has a saturation  
magnetization of from about 2 to about 3000 electromagnetic units per  
cubic centimeter, and it contains nanomagnetic particles with an average  
particle size of less than about 100 nanometers; the average coherence  
length between adjacent nanomagnetic particles is less than 100  
nanometers.

L4 ANSWER 5 OF 11 USPATFULL on STN  
AN 2005:92457 USPATFULL  
TI Medical device with low magnetic susceptibility  
IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard J., Rochester, NY, UNITED STATES  
Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES  
PI US 2005079132 A1 20050414  
AI US 2004-914691 A1 20040809 (10)  
RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun  
2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on  
26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser.  
No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part  
of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004,  
PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec  
2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on  
22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420,  
filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US

2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609

DT Utility  
FS APPLICATION  
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408, US  
CLMN Number of Claims: 127  
ECL Exemplary Claim: 1  
DRWN 52 Drawing Page(s)  
LN.CNT 17912

AB An assembly with a substrate, nanomagnetic material and magnetoresistive material. The nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter; and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers. The average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L4 ANSWER 6 OF 11 USPTATFULL on STN

AN 2005:62607 USPTATFULL

TI Biocompatible materials

IN Ulbricht, Mathias, Berlin, GERMANY, FEDERAL REPUBLIC OF  
Thom, Volkmar, Arlington, MA, UNITED STATES  
Jankova, Katja, Burgas, BULGARIA  
Altankov, George, Sofia, BULGARIA  
Jonsson, Gunnar, Vaerloese, DENMARK

PI US 2005053642 A1 20050310

AI US 2003-362677 A1 20030815 (10)

WO 2001-DK557 20010823

PRAI DK 2000-1250 20000823

DT Utility

FS APPLICATION

LREP Browdy and Neimark, Suite 300, 624 Ninth Street NW, Washington, DC,  
20001

CLMN Number of Claims: 125

ECL Exemplary Claim: 1

DRWN 31 Drawing Page(s)

LN.CNT 6442

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention teaches a novel approach of creating biocompatible surfaces, said surfaces being capable of functionally interact with biological material. Said biocompatible surfaces comprise at least two components, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocompatible surfaces. The novel approach is used on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The thus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physisorption or chemisorption, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. Amount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological



material to a hydrophobic substratum surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 11 USPATFULL on STN  
AN 2005:30367 USPATFULL  
TI Medical device with low magnetic susceptibility  
IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard Jay, Rochester, NY, UNITED STATES  
PI US 2005025797 A1 20050203  
AI US 2004-887521 A1 20040707 (10)  
RLI Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar  
2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on  
24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198,  
filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US  
2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser.  
No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part  
of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING  
Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003,  
PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr  
2003, GRANTED, Pat. No. US 6815609  
DT Utility  
FS APPLICATION  
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408  
CLMN Number of Claims: 137  
ECL Exemplary Claim: 1  
DRWN 42 Drawing Page(s)  
LN.CNT 17461  
AB An assembly that contains a medical device and biological material  
within which the medical device is disposed. The assembly has a magnetic  
susceptibility within the range of plus or minus 1+10.sup.-3  
centimeter-gram-seconds

L4 ANSWER 8 OF 11 USPATFULL on STN  
AN 2004:321764 USPATFULL  
TI Therapeutic assembly  
IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard J., Rochester, NY, UNITED STATES  
Lanzafame, John, Victor, NY, UNITED STATES  
Weiner, Michael L., Webster, NY, UNITED STATES  
Connelly, Patrick R., Rochester, NY, UNITED STATES  
PI US 2004254419 A1 20041216  
AI US 2004-867517 A1 20040614 (10)  
RLI Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar  
2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on  
25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045,  
filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US  
2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser.  
No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part  
of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING  
Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003,  
PENDING  
DT Utility  
FS APPLICATION  
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408  
CLMN Number of Claims: 175  
ECL Exemplary Claim: CLM-1-177  
DRWN 40 Drawing Page(s)  
LN.CNT 16208

AB A therapeutic assembly that contains a therapeutic agent, a cytotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagnetic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

L4 ANSWER 9 OF 11 USPTAFULL on STN  
AN 2004:268745 USPTAFULL  
TI Novel nanomagnetic particles  
IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard J., Rochester, NY, UNITED STATES  
PI US 2004210289 A1 20041021  
AI US 2004-808618 A1 20040324 (10)  
RLI Continuation-in-part of Ser. No. US 2003-366082, filed on 13 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2002-324773, filed on 18 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-90553, filed on 4 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2002-229183, filed on 26 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-242969, filed on 13 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-260247, filed on 30 Sep 2002, GRANTED, Pat. No. US 6673999 Continuation-in-part of Ser. No. US 2002-273738, filed on 18 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671 Continuation-in-part of Ser. No. US 2002-313847, filed on 7 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671  
DT Utility  
FS APPLICATION  
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408  
CLMN Number of Claims: 98  
ECL Exemplary Claim: 1  
DRWN 51 Drawing Page(s)  
LN.CNT 11684

AB A composition containing nanomagnetic particles. The, nanomagnetic particles have an average particle size of less than about 100 nanometers, a saturation magnetization of from about 2 to about 2,000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a squareness of from about 0.05 to about 1.0; the average coherence length between adjacent nanomagnetic particles is less than about 100 nanometers; and the nanomagnetic particles are at least triatomic.

L4 ANSWER 10 OF 11 USPTAFULL on STN  
AN 1999:36949 USPTAFULL  
TI Engineering oral tissues  
IN Mooney, David J., Ann Arbor, MI, United States  
Rutherford, Robert B., Ann Arbor, MI, United States  
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)  
PI US 5885829 19990323  
AI US 1997-864494 19970528 (8)  
PRAI US 1996-18450P 19960528 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy  
LREP Arnold, White & Durkee  
CLMN Number of Claims: 109

ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 8001

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for regenerating dental and oral tissues from viable cells using ex vivo culture on a structural matrix. The regenerated oral tissues and tissue-matrix preparations thus provided have both clinical applications in dentistry and oral medicine and are also useful in in vitro toxicity and biocompatibility testing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 11 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN  
AN 2004-191035 [18] WPINDEX  
DNC C2004-075267  
TI Use of electron-beam radiation for depolymerization of glycosaminoglycans e.g. heparin, dermatan and heparansulfate.  
DC A11 A96 B04  
IN DE AMBROSI, L; GONELLA, S; IANNAcone, N; NESTI, S; TORRI, G; VISMARA, E; IANNAcone, N  
PA (DERI-N) LAB DERIVATI ORGANICI SPA; (DAMB-I) DE AMBROSI L; (GONE-I) GONELLA S; (IANN-I) IANNAcone N; (NEST-I) NESTI S; (TORR-I) TORRI G; (VISM-I) VISMARA E  
CYC 103  
PI WO 2004000886 A1 20031231 (200418)\* EN 15  
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS  
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT  
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA  
ZM ZW  
AU 2003279381 A1 20040106 (200447)  
EP 1572749 A1 20050914 (200560) EN  
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV  
MC MK NL PT RO SE SI SK TR  
US 2005240013 A1 20051027 (200571)  
ADT WO 2004000886 A1 WO 2003-EP6446 20030618; AU 2003279381 A1 AU 2003-279381  
20030618; EP 1572749 A1 EP 2003-740278 20030618, WO 2003-EP6446 20030618;  
US 2005240013 A1 WO 2003-EP6446 20030618, US 2005-518980 20050531  
FDT AU 2003279381 A1 Based on WO 2004000886; EP 1572749 A1 Based on WO  
2004000886  
PRAI IT 2002-MI1372 20020621  
AN 2004-191035 [18] WPINDEX  
AB WO2004000886 A UPAB: 20040316  
NOVELTY - Depolymerization of glycosaminoglycans is carried out  
using electron-beam radiation.  
USE - For depolymerization of glycosaminoglycans  
e.g. heparin (claimed), which are natural products of high  
pharmaceutical interest.  
ADVANTAGE - The electron-beam radiation reduces  
molecular weight of glycosaminoglycans without substantially modifying  
the chemical structure and can provide low to ultra-low molecular weight  
heparin with high S content.  
Dwg.0/0

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
73.13	73.34

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:03:16 ON 10 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2006 VOL 145 ISS 7  
FILE LAST UPDATED: 9 Aug 2006 (20060809/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s Ambrosi Luigi De/AU  
L5 0 AMBROSI LUIGI DE/AU

=> s De Ambrosi Luigi/AU  
L6 17 DE AMBROSI LUIGI/AU

=> s 16 and glycosaminoglycan or heparin  
10505 GLYCOSAMINOGLYCAN  
12709 GLYCOSAMINOGLYCANS  
15465 GLYCOSAMINOGLYCAN  
(GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)  
47654 HEPARIN  
1838 HEPARINS  
47777 HEPARIN  
(HEPARIN OR HEPARINS)  
L7 47777 L6 AND GLYCOSAMINOGLYCAN OR HEPARIN

=> s 16 and glycosaminoglycan  
10505 GLYCOSAMINOGLYCAN  
12709 GLYCOSAMINOGLYCANS  
15465 GLYCOSAMINOGLYCAN  
(GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)  
L8 5 L6 AND GLYCOSAMINOGLYCAN

=> dis l8 1-5 bib abs

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1036909 CAPLUS  
DN 141:406140  
TI Glycosaminoglycans for treatment emotional dysfunctions  
IN Cornelli, Umberto; De Ambrosi, Luigi; Lorens, Stanley; Fareed,  
Jawed; Lee, John; Hanin, Israel; Mervis, Ronald  
PA Italy  
SO PCT Int. Appl., 20 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004103381	A1	20041202	WO 2004-EP50860	20040519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004241748 A1 20041202 AU 2004-241748 20040519  
 CA 2526201 AA 20041202 CA 2004-2526201 20040519  
 EP 1631298 A1 20060308 EP 2004-741606 20040519

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1791416 A 20060621 CN 2004-80013609 20040519  
 NO 2005006089 A 20060209 NO 2005-6089 20051221

PRAI IT 2003-MI1023 A 20030521  
 WO 2004-EP50860 W 20040519

AB The invention discloses the use of glycosaminoglycan fractions having an average mol. weight of 2400 D for the preparation of pharmaceutical compns.

suitable for the treatment of emotional dysfunctions, especially depressive disorders, anxiety disorders, anxiety neurosis, agitation, confusion.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:960075 CAPLUS

DN 141:397168

TI Depolymerization of glycosaminoglycans by UV radiation

IN De Ambrosi, Luigi; Vismara, Elena

PA Laboratori Derivati Organici S.P.A., Italy

SO Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1475391	A1	20041110	EP 2003-76388	20030509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2004099256	A1	20041118	WO 2004-EP50723	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1641831 A1 20060405 EP 2004-741520 20040506  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI EP 2003-76388 A 20030509  
 WO 2004-EP50723 W 20040506

AB Glycosaminoglycans with reduced mol. weight suitable for pharmaceutical applications were manufactured by depolymn. of high-mol.-weight glycosaminoglycans using UVC radiation. For example, UV irradiation

of 10% aqueous solution of heparin Na salt (mol. weight 13,000 Da) for 16 at 30° gave a degraded product having mol. weight 5000 Da and showing anticoagulant activity 114 U/mg.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:733067 CAPLUS  
DN 139:247126  
TI Process for the depolymerization of glycosaminoglycans and oligomer products  
IN Gonella, Sergio; De Ambrosi, Luigi; Vismara, Elena  
PA Laboratori Derivati Organici S.p.A., Italy  
SO Eur. Pat. Appl., 9 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1344781	A1	20030917	EP 2002-425142	20020312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2446695	AA	20030918	CA 2003-2446695	20030311
	WO 2003076474	A1	20030918	WO 2003-EP2462	20030311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003218725	A1	20030922	AU 2003-218725	20030311
	EP 1404720	A1	20040407	EP 2003-711967	20030311
	EP 1404720	B1	20050622		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005520005	T2	20050707	JP 2003-574689	20030311
	AT 298349	E	20050715	AT 2003-711967	20030311
	PT 1404720	T	20051130	PT 2003-711967	20030311
	ES 2244929	T3	20051216	ES 2003-3711967	20030311
	US 2004186279	A1	20040923	US 2003-477293	20031110
PRAI	EP 2002-425142	A	20020312		
	WO 2003-EP2462	W	20030311		

OS MARPAT 139:247126

AB The invention relates to a process for the depolymn. of glycosaminoglycans characterized using high-energy radiation in the presence of an organic compound selected from the group consisting of ethers, alcs., aldehydes, amides and formic acid. Intermediate depolymd. heparin having Mw 1000-5500, absorbance at 400 nm <0.300, and ratio SO3-/COO- equal to or higher than in the starting heparin. The intermediate depolymd. heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired mol. weight fraction.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2000:824113 CAPLUS  
DN 133:366401  
TI Glycosaminoglycans having an average molecular weight equal to

2400 D suitable for the treatment of senile dementia  
IN Cornelli, Umberto; De Ambrosi, Luigi; Hanin, Israel; Fareed,  
Jawed; Lee, John; Lorens, Stanley; Mervis, Ronald F.  
PA Italy  
SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000069444	A1	20001123	WO 2000-EP4311	20000512
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 99MI1066	A1	20001114	IT 1999-MI1066	19990514
	IT 1312107	B1	20020404		
	CA 2373975	AA	20001123	CA 2000-2373975	20000512
	EP 1181024	A1	20020227	EP 2000-925281	20000512
	EP 1181024	B1	20050209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	JP 2002544233	T2	20021224	JP 2000-617903	20000512
	AU 764743	B2	20030828	AU 2000-44052	20000512
	AT 288761	E	20050215	AT 2000-925281	20000512
	RU 2248800	C2	20050327	RU 2001-130882	20000512
	PT 1181024	T	20050630	PT 2000-925281	20000512
	ES 2237425	T3	20050801	ES 2000-925281	20000512
	NO 2001005544	A	20020114	NO 2001-5544	20011113
	ZA 2001009331	A	20020618	ZA 2001-9331	20011113
	HK 1039903	A1	20050826	HK 2002-101550	20020228
	US 6979680	B1	20051227	US 2002-48542	20020405
PRAI	IT 1999-MI1066	A	19990514		
	WO 2000-EP4311	W	20000512		

AB The present invention relates to the use of glycosaminoglycans  
having an average mol. weight equal to 2,400 D for the preparation of  
pharmaceutical  
compsn. suitable for the treatment of senile dementia, in particular for  
the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's  
Type) and of the cerebral neurol. lesions from ictus and from traumas.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1989:141519 CAPLUS  
DN 110:141519  
TI Controlled preparation of low molecular weight glucosaminoglycans  
IN Ferrari, Gianni; Recchia, Walter; De Ambrosi, Luigi  
PA Mediolanum Farmaceutici S.r.l., Italy; Laboratori Derivati Organici S.p.A.  
SO Eur. Pat. Appl., 10 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 269937	A2	19880608	EP 1987-116862	19871116
	EP 269937	A3	19890308		
	EP 269937	B1	19910220		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

NO 8704777	A	19880525	NO 1987-4777	19871116
US 4987222	A	19910122	US 1987-120953	19871116
AT 60924	E	19910315	AT 1987-116862	19871116
DK 8706023	A	19880915	DK 1987-6023	19871117
AU 8781609	A1	19880526	AU 1987-81609	19871123
AU 603622	B2	19901122		
CA 1305134	A1	19920714	CA 1987-552481	19871123
FI 8705185	A	19880525	FI 1987-5185	19871124
FI 88045	B	19921215		
FI 88045	C	19930325		
JP 63213502	A2	19880906	JP 1987-294255	19871124
JP 05088881	B4	19931224		
PRAI IT 1986-22434	A	19861124		
EP 1987-116862	A	19871116		

AB Glucosylaminoglycans with mol. weight 1000-35,000 and antithrombotic, fibrinolytic, antiatherogenic, anti-inflammatory, and heparin cofactor II activation activities are manufactured by static or dynamic stepwise  $\gamma$ -irradiation of high-mol.-weight glucosaminoglycans, e.g., Na heparin (I), at doses 2.5-20 Mrads with cooling between the steps. I 16 g was irradiated with successive treatments of 2.5 Mrads each to a total of 17.5 Mrads, and worked up to give a powder, which was purified by reverse osmosis and a Sephadex 50 column to give 5 g product. A Na salt of the purified product (mol. weight 5000) exhibited heparin activity 20 U/mg USP, active-partial-thromboplastin-time activity 15 U/mg, organic S content 10.8%, uronic acid content 24.7%, and rotary power 49°.

=> s Iannaccone Nicola/AU  
L9 0 IANNACCONI NICOLA/AU

=> s Gonella Sergio/AU  
L10 10 GONELLA SERGIO/AU

=> dis 110 1-10 bib abs

L10 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:229587 CAPLUS  
DN 144:275933  
TI One-step process for sulfation and depolymerization of chondroitin  
IN Gonella, Sergio; Bensi, Donata; Maggia, Giorgio  
PA Laboratori Derivati Organici S.p.A., Italy  
SO Eur. Pat. Appl., 5 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1634893	A1	20060315	EP 2004-104404	20040913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006077227	A2	20060323	JP 2005-117569	20050414
PRAI	EP 2004-104404	A	20040913		

AB The invention concerns a process for the preparation of chondroitin polysulfate with intrinsic viscosity 0.09-0.18 and organic sulfur content 25.8-37.3 %, wherein chlorosulfonic acid is added to a formamide solution of chondroitin at a rate such that the temperature of the formamide solution is kept at 15°-40°. The activity of the obtained chondroitin polysulfate in the inhibition of Hyaluronidase is between 14 and 29.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN



AN 2005:345925 CAPLUS

DN 142:375459

TI Multistep process for the physical depolymerization of heparin and products obtained therefrom

IN De Ambrosi, Luigi; Gonella, Sergio; Bensi, Donata; Torri, Giangiacomo; Bisio, Antonella; Vismara, Elena

PA Laboratori Derivati Organici S.P.A., Italy

SO Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1524276	A1	20050420	EP 2003-23377	20031016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	WO 2005035587	A2	20050421	WO 2004-EP52531	20041013
	WO 2005035587	A3	20050616		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1675875	A2	20060705	EP 2004-804499	20041013
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-23377	A	20031016		
	WO 2004-EP52531	W	20041013		

AB In the process heparin is subjected to at least two  $\gamma$ -ray irradiations and wherein between 2 irradiation steps the depolymd. heparin is subjected to a separation step and only a fraction of the depolymd. heparin obtained from the first irradiation is subjected to the second irradiation step.

It is also directed to heparin-derived oligosaccharide fractions obtainable by the process of the invention.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:2921 CAPLUS

DN 140:61261

TI Radiation process for the physical depolymerization of glycosaminoglycanes and products obtained therefrom

IN De Ambrosi, Luigi; Iannaccone, Nicola; Gonella, Sergio; Vismara, Elena; Nesti, Solitario; Torri, Giangiacomo

PA Laboratori Derivati Organici S.P.A., Italy; De Ambrosi, Luigi

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000886	A1	20031231	WO 2003-EP6446	20030618
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2488089 AA 20031231 CA 2003-2488089 20030618  
 AU 2003279381 A1 20040106 AU 2003-279381 20030618  
 EP 1572749 A1 20050914 EP 2003-740278 20030618  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 US 2005240013 A1 20051027 US 2005-518980 20050531  
 PRAI IT 2002-MI1372 A 20020621  
 WO 2003-EP6446 W 20030618

OS MARPAT 140:61261

AB The invention relates to a process for the depolymn. of  
 glycosaminoglycanes characterized by the use of electron beam radiation,  
 optionally in the presence of an organic compound selected from the group  
 consisting of ethers, alcs., aldehydes, amides and formic acid. The  
 invention also relates to the intermediate depolymd. heparin obtained by  
 the process. The intermediate depolymd. heparin can be dissolved in a  
 buffer solution and fractionated by Gel Permeation for obtaining the desired  
 mol. weight

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:998783 CAPLUS

DN 140:357575

TI Controlled  $\gamma$ -ray irradiation of heparin generates oligosaccharides  
 enriched in highly sulfated sequences

AU Bisio, Antonella; Guglieri, Sara; Frigerio, Marta; Torri, Giangiacomo;  
 Vismara, Elena; Cornelli, Umberto; Bensi, Donata; Gonella, Sergio  
 ; De Ambrosi, Luigi

CS Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, Milan, 20133,  
 Italy

SO Carbohydrate Polymers (2004), 55(1), 101-112

CODEN: CAPOD8; ISSN: 0144-8617

PB Elsevier Science B.V.

DT Journal

LA English

AB Controlled phys. depolymn. of heparin was performed in aqueous solution in the  
 presence of isopropanol by  $\gamma$ -irradiation Isopropanol both makes  
 selective the radical-induced scission of the glycosidic linkage involved  
 in the depolymn. and acts as hydrogen donor scavenger of heparin  
 intermediate radicals that usually result in UV-absorbing byproducts.  
 Several prepns. of heparin-derived oligosaccharides (HDO) were  
 reproducibly obtained from different unfractionated heparins (UFH). From  
 each preparation, an intermediate fraction with an average mol. weight of  
 about 2200

Da ( $\gamma$ -HDO) was isolated by gel permeation chromatog. and its  
 sulfation pattern was characterized by NMR spectroscopy. The comparison  
 of the sulfation pattern of HDO with that of parent UFHs revealed a  
 significant decrease in the relative content of D-glucuronic acid with  
 respect to the total amount of uronic acid. Further  $\gamma$ -ray treatments  
 of heparin chains that survived the first depolymn. procedure led to a  
 further decrease of D-glucuronic acid and also slightly reduced the  
 content of N-acetyl-glucosamine residues, thus enriching oligosaccharide  
 chains in the highly sulfated sequences. MALDI mass spectrometric anal.  
 of oligomeric components indicated that  $\gamma$ -HDO prevalently contains  
 highly sulfated chains (tetra- to deca-saccharides, including both odd and  
 even number of mono-saccharidic units) chiefly constituted of repeating  
 sequences of the tri-sulfated disaccharide L-iduronic acid 2-sulfate

(1,4)-D-glucosamine-N,6-disulfate.  $\gamma$ -Irradiation in the presence of isopropanol thus generated heparin fragments largely preserving the prevalent structure of the parent heparin and involved glucuronic acid as the major site of cleavage. This procedure was repeated twice. All the products obtained have been structurally characterized and compared with parent UFHs also in terms of mol. weight distribution and anticoagulant (antifactor Xa) activity in vitro.

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:733067 CAPLUS

DN 139:247126

TI Process for the depolymerization of glycosaminoglycans and oligomer products

IN Gonella, Sergio; De Ambrosi, Luigi; Vismara, Elena

PA Laboratori Derivati Organici S.p.A., Italy

SO Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1344781	A1	20030917	EP 2002-425142	20020312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2446695	AA	20030918	CA 2003-2446695	20030311
	WO 2003076474	A1	20030918	WO 2003-EP2462	20030311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003218725	A1	20030922	AU 2003-218725	20030311
	EP 1404720	A1	20040407	EP 2003-711967	20030311
	EP 1404720	B1	20050622		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005520005	T2	20050707	JP 2003-574689	20030311
	AT 298349	E	20050715	AT 2003-711967	20030311
	PT 1404720	T	20051130	PT 2003-711967	20030311
	ES 2244929	T3	20051216	ES 2003-3711967	20030311
	US 2004186279	A1	20040923	US 2003-477293	20031110
PRAI	EP 2002-425142	A	20020312		
	WO 2003-EP2462	W	20030311		

OS MARPAT 139:247126

AB The invention relates to a process for the depolymn. of glycosaminoglycans characterized using high-energy radiation in the presence of an organic compound selected from the group consisting of ethers, alcs., aldehydes, amides and formic acid. Intermediate depolyd. heparin having Mw 1000-5500, absorbance at 400 nm <0.300, and ratio SO<sub>3</sub>-/COO- equal to or higher than in the starting heparin. The intermediate depolyd. heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired mol. weight fraction.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:72798 CAPLUS  
 DN 136:123693  
 TI Composition containing heparin fractions with molecular weight equal to 5200D  
 IN De Ambrosi, Luigi; Gonella, Sergio; Marcenaro, Francesca  
 PA Italy  
 SO U.S. Pat. Appl. Publ., 9 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002010152	A1	20020124	US 1998-213538	19981217
PRAI	IT 1997-MI2835	A	19971219		

AB A composition contains heparin fractions having reproducible characteristics with average mol. weight (MW) of 5200 D obtained by depolymn. with  $\gamma$ -radiation and subsequent fractionation by gel permeation, having high antithrombotic properties and particularly suitable for the prophylaxis and the therapy of the alterations of the plasmatic homeostasis. Thus, 100 g sodium heparin obtained from animal extraction, and having an activity equal to 190 U/mg and MW of 15,175D was dissolved in water and the solution was subjected to a 130 kGy- $\gamma$ -ray irradiation. The irradiated solution was further purified in 3% NaCl. The solution was freeze dried and the product was fractionated on gel permeation chromatog.

L10 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:858550 CAPLUS

DN 137:98817

TI Preserving the original heparin structure of a novel low molecular weight heparin by  $\gamma$ -irradiation

AU Bisio, Antonella; De Ambrosi, Luigi; Gonella, Sergio; Guerrini, Marco; Guglieri, Sara; Maggia, Giorgio; Torri, Giangiacomo

CS "G. Ronzoni" Institute for Chemical and Biochemical Research, Milan, 20133, Italy

SO Arzneimittelforschung (2001), 51(10), 806-813

CODEN: ARZNAD; ISSN: 0004-4172

PB Editio Cantor Verlag

DT Journal

LA English

AB Several prepns. of low mol. weight heparins (LMWHs) obtained by phys. depolymn. (irradiation with  $\gamma$ -rays) of pig mucosal heparin have been characterized by mono- and two-dimensional NMR spectroscopy. Integration of typical  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR signals provided a useful quantification of their sulfation pattern. The availability of the corresponding parent heparins showed that the original structure (including that of the active site for antithrombin, as also confirmed by affinity chromatog.) had not been significantly modified by the depolymn. procedure. This process involves only a slight decrease of undersulfated sequences. A peculiarity of  $\gamma$ -LMWH is the absence of the "linkage region", commonly present in unmodified heparins and most LMWHs.

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:721473 CAPLUS

DN 129:339870

TI Complexes consisting of Fe(III), a polyhydroxylated compound, and ovalbumin, preparation thereof, and use in the treatment of sideropenic anemia

IN Gonella, Sergio

PA Laboratori Derivati Organici S.P.A., Italy

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 875249	A1	19981104	EP 1998-107887	19980428
	EP 875249	B1	20030312		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

PRAI IT 1997-MI1012 A 19970430

AB Organic complexes of Fe (III) are provided which consist of Fe (III), a polyhydroxylated compound (e.g. mannitol), and ovalbumin. The complexes of the invention are suitable for use in the treatment of sideropenic anemia. A process for producing the complexes is also disclosed.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:378875 CAPLUS

DN 125:81007

TI Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy

AU Casu, Benito; Guerrini, Marco; Naggi, Annamaria; Torri, Giangiacomo; De-Ambrosi, Luigi; Boveri, Giuliano; Gonella, Sergio; Cedro, Armando; Ferro, Laura; et al.

CS "G. Ronzoni" Inst. Chem. Biochem. Res., Milan, I-20133, Italy

SO Arzneimittelforschung (1996), 46(5), 472-477

CODEN: ARZNAD; ISSN: 0004-4172

PB Cantor

DT Journal

LA English

AB Though differing only slightly in their degrees of sulfation, heparin preps. from pig mucosa and those from beef mucosa have consistently different <sup>13</sup>C- and <sup>1</sup>H-NMR spectra, which provide useful fingerprints for distinguishing the two types of heparin. Integrated areas of NMR signals associated with minor, undersulfated sequences (assigned by comparison with mono-dimensional spectra of selectively desulfated heparins and by anal. of two-dimensional spectra of heparins prepared from pig and beef mucosa) permit quantitation of differences in sulfation patterns. Undersulfation of pig mucosal heparins at position 6 of the hexosamine units, determined by <sup>13</sup>C-NMR and expressed as percent glucosamines nonsulfated at C6 referred to total glucosamines, is substantially lower for pig mucosal heparins than for beef mucosal heparins (16.9-21.7% vs 36.7-40.7%; average values: 18.6% vs 40.3%). By contrast, undersulfation at position 2 of the iduronic acid units, determined by <sup>1</sup>H-NMR and expressed as percent nonsulfated iduronic acid referred to total (sulfated + nonsulfated) iduronic acid is significantly higher for pig mucosal preps. (9.6-13.5% vs 2.1-2.7%; average values: 12.7% vs 2.3%). Pig mucosal heparins also have a significantly higher content of 3-O-sulfated glucosamine units, which are markers for the active site of heparin for antithrombin-III.

L10 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:908227 CAPLUS

DN 123:321954

TI Differentiation of beef and pig mucosal heparins by NMR spectroscopy

AU Casu, Benito; Guerrini, Marco; Naggi, Annamaria; Torri, Giangiacomo; De-Ambrosi, Luigi; Boveri, Giuliano; Gonella, Sergio

CS G. Ronzoni Inst. for Chem. and Biochem. Res., Milan, Italy

SO Thrombosis and Haemostasis (1995), 74(4), 1205

CODEN: THHADQ; ISSN: 0340-6245

PB Schattauer

DT Journal

LA English

AB The structural characterization of title heparins by <sup>13</sup>C-NMR spectroscopy

is reported.

=> s Vismara Elena/AU  
L11 59 VISMARA ELENA/AU

=> s l11 and glycosaminoglycan  
10505 GLYCOSAMINOGLYCAN  
12709 GLYCOSAMINOGLYCANS  
15465 GLYCOSAMINOGLYCAN  
(GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)  
L12 2 L11 AND GLYCOSAMINOGLYCAN

=> dis l12 1-2 bib abs

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:960075 CAPLUS  
DN 141:397168  
TI Depolymerization of glycosaminoglycans by UV radiation  
IN De Ambrosi, Luigi; Vismara, Elena  
PA Laboratori Derivati Organici S.P.A., Italy  
SO Eur. Pat. Appl., 8 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1475391	A1	20041110	EP 2003-76388	20030509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	WO 2004099256	A1	20041118	WO 2004-EP50723	20040506
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1641831	A1	20060405	EP 2004-741520	20040506
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-76388	A	20030509		
	WO 2004-EP50723	W	20040506		
AB	Glycosaminoglycans with reduced mol. weight suitable for pharmaceutical applications were manufactured by depolymn. of high-mol.-weight glycosaminoglycans using UVC radiation. For example, UV irradiation of 10% aqueous solution of heparin Na salt (mol. weight 13,000 Da) for 16 at 30° gave a degraded product having mol. weight 5000 Da and showing anticoagulant activity 114 U/mg.				

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:733067 CAPLUS  
DN 139:247126  
TI Process for the depolymerization of glycosaminoglycans and oligomer products  
IN Gonella, Sergio; De Ambrosi, Luigi; Vismara, Elena  
PA Laboratori Derivati Organici S.p.A., Italy

SO Eur. Pat. Appl., 9 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1344781	A1	20030917	EP 2002-425142	20020312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2446695	AA	20030918	CA 2003-2446695	20030311
	WO 2003076474	A1	20030918	WO 2003-EP2462	20030311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003218725	A1	20030922	AU 2003-218725	20030311
	EP 1404720	A1	20040407	EP 2003-711967	20030311
	EP 1404720	B1	20050622		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005520005	T2	20050707	JP 2003-574689	20030311
	AT 298349	E	20050715	AT 2003-711967	20030311
	PT 1404720	T	20051130	PT 2003-711967	20030311
	ES 2244929	T3	20051216	ES 2003-3711967	20030311
	US 2004186279	A1	20040923	US 2003-477293	20031110
PRAI	EP 2002-425142	A	20020312		
	WO 2003-EP2462	W	20030311		
OS	MARPAT 139:247126				

AB The invention relates to a process for the depolymn. of glycosaminoglycans characterized using high-energy radiation in the presence of an organic compound selected from the group consisting of ethers, alcs., aldehydes, amides and formic acid. Intermediate depolymd. heparin having Mw 1000-5500, absorbance at 400 nm <0.300, and ratio SO<sub>3</sub><sup>-</sup>/COO<sup>-</sup> equal to or higher than in the starting heparin. The intermediate depolymd. heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired mol. weight fraction.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Nesti Solitario/AU  
L13 6 NESTI SOLITARIO/AU

=> dis l13 1-6 bib abs

L13 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:733709 CAPLUS  
TI Inclusion complexes between a cyclodextrin derivative and insect repellents  
IN Ranaldo, Angelo Marco; Nesti, Solitario; Corsi, Leopoldo  
PA Pointex S.p.A., Italy  
SO PCT Int. Appl., 44 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006077604	A1	20060727	WO 2005-IT26	20050119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI WO 2005-IT26 20050119

AB The invention relates to a stable liquid water-based composition having a repellent activity toward insects, comprising an inclusion compound between a cyclodextrin derivative and a repellent. The invention also relates to a method of use of the composition for impregnating textile fibers and/or fabrics, so as to give them repellent activity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:33486 CAPLUS

TI Apparatus and method for inserting and pre-feeding a sliver into a spinning unit

IN Nesti, Solitario; Barbieri, Marco; Colussi, Vittorio

PA Ministero Dell'istruzione, Dell'universita'e Della Ricerca, Italy

SO PCT Int. Appl.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006003679	A1	20060112	WO 2004-IT367	20040630
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI WO 2004-IT367 20040630

AB Equipement (10) for inserting and prefeeding a sliver (N) into a feed opening (A) of a spinning unit (F). The sliver is contained in a spinning can (V) located at the spinning unit (F) and has an end (4) outside the can (V). The equipment (10) comprises means (6, 7, 8) for seizing an end (4) of the sliver (N) and pulling a terminal portion (5) of the end (4), means (13, 14) for tapering the remaining terminal portion (11a) of the end (4) of the sliver (N), means (9, 18) for seizing and moving the end (4) of the sliver (N) to insert the tapered terminal portion (17) into the feed opening (A) of the spinning unit (F) and corresponding activating means (32, 33, 34) to activate the seizing and pulling means (6, 7, 8), the tapering means (13, 14) and the seizing and moving means (9, 18). Means (35, 37) are provided to control the prefeeding of the sliver (N) into the feed opening (A) of the spinning unit (F).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:895488 CAPLUS  
 TI Process and apparatus for the transformation of yarns  
 IN Marrani, Pierluigi; Nesti, Solitario; Barni, Marcello;  
 Poggiali, Maurizio  
 PA Unitech Textile Machinery S.P.A., Italy; Pecci Filati S.P.A.  
 SO Eur. Pat. Appl.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1471171	A2	20041027	EP 2004-425185	20040317
	EP 1471171	A3	20050914		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
	US 2004216278	A1	20041104	US 2004-802295	20040317
	US 7013542	B2	20060321		
PRAI	IT 2003-FI116	A	20030424		
AB	Process for the mechanical transformation of a thread (F) of vegetable, animal or artificial or synthetic origin, characterized in that it includes abrading the thread (F) when the latter is supported in the air between two supports (55, 56).				

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:2921 CAPLUS  
 DN 140:61261  
 TI Radiation process for the physical depolymerization of glycosaminoglycanes and products obtained therefrom  
 IN De Ambrosi, Luigi; Iannaccone, Nicola; Gonella, Sergio; Vismara, Elena; Nesti, Solitario; Torri, Giangiacomo  
 PA Laboratori Derivati Organici S.P.A., Italy; De Ambrosi, Luigi  
 SO PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000886	A1	20031231	WO 2003-EP6446	20030618
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2488089	AA	20031231	CA 2003-2488089	20030618
	AU 2003279381	A1	20040106	AU 2003-279381	20030618
	EP 1572749	A1	20050914	EP 2003-740278	20030618
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2005240013	A1	20051027	US 2005-518980	20050531
PRAI	IT 2002-MI1372	A	20020621		
	WO 2003-EP6446	W	20030618		
OS	MARPAT 140:61261				
AB	The invention relates to a process for the depolymn. of glycosaminoglycanes characterized by the use of electron beam radiation, optionally in the presence of an organic compound selected from the group				

consisting of ethers, alcs., aldehydes, amides and formic acid. The invention also relates to the intermediate depolymd. heparin obtained by the process. The intermediate depolymd. heparin can be dissolved in a buffer solution and fractionated by Gel Permeation for obtaining the desired mol. weight

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:812086 CAPLUS

TI Unwinding and balloon-separating device for twisting/doubling machines for yarns

IN Nesti, Solitario; Barbieri, Marco

PA Tecnotessile Societa Nazionale Di Ricerca Tecnologica R.L., Italy

SO PCT Int. Appl.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003085180	A1	20031016	WO 2003-IB1218	20030403
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003219349	A1	20031020	AU 2003-219349	20030403
PRAI IT 2002-UD74	U	20020404		
WO 2003-IB1218	W	20030403		

AB Unwinding-separating device (10) for twisting/doubling assemblies (20) for yarns (11) wound in bobbins (12), in which each of the yarns (11) defines a first inner segment (11a), and a second outer segment (11b) that under normal working conditions constitutes the balloon. The unwinding-separating device (10) is assembled rotatable in correspondence with one end of the bobbin (12) and comprises a first thread-guide element (14) in which the first inner segment (11a) of yarn passes. The first thread-guide element (14) is supported by a circular element (16) mounted coaxial with the bobbin (12). The circular element (16) is provided with separation means (13) able to separate the first inner segment (11a) from the second outer segment (11b) of the yarn.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:752690 CAPLUS

DN 139:262402

TI Free-radical functionalized polysaccharides

IN Torri, Giangiacomo; Vismara, Elena; Alberti, Angelo; Bertini, Sabrina; Ciardelli, Gianluca; Gastaldi, Giuseppe; Nesti, Solitario

PA Tecnotessile Societa Nazionale di Ricerca Tecnologica r.L., Italy; Istituto di Chimica E Biochimica "G. Ronzoni"

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI EP 1347000 A1 20030924 EP 2002-425172 20020320  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
WO 2003078471 A1 20030925 WO 2003-EP2910 20030320  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
AU 2003226673 A1 20030929 AU 2003-226673 20030320  
EP 1492820 A1 20050105 EP 2003-744381 20030320  
EP 1492820 B1 20060705  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
US 2005108832 A1 20050526 US 2003-506619 20030320  
PRAI EP 2002-425172 A 20020320  
WO 2003-EP2910 W 20030320

AB The invention concerns a method for functionalizing polysaccharides using a source or free radicals which forms stable radicals on the polysaccharide structure and wherein the formed radical reacts with a functionalized unsatd. compound, characterized in that the method comprises two steps: a first step, wherein the free radical on the polysaccharide chain is formed, and a second step, wherein said radical reacts with the unsatd. compound in the absence of the radical source. The invention also relates to the functionalized polysaccharide obtained by this process. The source of free radicals is a chemical source, namely Fenton's reagent, or a phys. source, namely cold plasma and electron beam radiation. The polysaccharides are selected from the group consisting of flax, cellulose, rayon, cotton, and starch. The polysaccharides can be also together with one or more natural or synthetic fibers, i.e., in combination with silk. polyamide, polyester, polyolefin, or acrylic fibers.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Torri Giangiaocomo/AU  
L14 0 TORRI GIANGLIAOCOMO/AU

=> dis hist

(FILE 'HOME' ENTERED AT 09:58:30 ON 10 AUG 2006)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, JICST-EPLUS, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, MEDLINE, BIOSIS, EMBASE' ENTERED AT 09:58:54 ON 10 AUG 2006

L1 116925 S GLYCOSAMINOGLYCAN  
L2 32089 S L1 AND HEPARIN  
L3 947 S L2 AND DEPOLYM?  
L4 11 S L3 AND (ELECTRON(A) BEAM)

FILE 'CAPLUS' ENTERED AT 10:03:16 ON 10 AUG 2006

L5 0 S AMBROSI LUIGI DE/AU  
L6 17 S DE AMBROSI LUIGI/AU  
L7 47777 S L6 AND GLYCOSAMINOGLYCAN OR HEPARIN  
L8 5 S L6 AND GLYCOSAMINOGLYCAN  
L9 0 S IANNACONE NICOLA/AU  
L10 10 S GONELLA SERGIO/AU  
L11 59 S VISMARA ELENA/AU

L12	2 S L11 AND GLYCOSAMINOGLYCAN
L13	6 S NESTI SOLITARIO/AU
L14	0 S TORRI GIANGIAOCOMO/AU